Skip to main content

Market Overview

Cantor Fitzgerald Reiterates Buy Rating, $60 PT on Salix Pharmaceuticals Ltd.

Share:

In a report published Wednesday, Cantor Fitzgerald reiterated its Buy rating and $60.00 price target on Salix Pharmaceuticals Ltd. (NASDAQ: SLXP).

Cantor Fitzgerald noted, “Management has previously guided to a $150-200M opportunity for this product. We currently model 2013 revenues of $8M, growing to $102M in 2020 (Bloomberg 2013 consensus is $18M). There are approximately 940,000 diagnosed HIV patients in the U.S., but we estimate that only a small portion (~15%) experience anti-retroviral therapy-related diarrhea. Because of its novel mechanism of action (as a chloride secretion blocker) and relatively good tolerability we believe the drug may also generate some off-label trial in other diarrhea subtypes. Fulyzaq is patent-protected until 2018 and has five years NCE exclusivity as well as additional pending patents. Since the drug is a botanical, we believe that its manufacturing process should represent a strong barrier to entry for generic filers. Pricing has not yet been announced.”

Salix Pharmaceuticals Ltd. closed on Monday at $40.47.

Latest Ratings for SLXP

DateFirmActionFromTo
Mar 2015JefferiesDowngradesBuyHold
Feb 2015Cantor FitzgeraldDowngradesBuyHold
Feb 2015UBSDowngradesBuyNeutral

View More Analyst Ratings for SLXP
View the Latest Analyst Ratings

 

Related Articles (SLXP)

View Comments and Join the Discussion!

Posted-In: Cantor FitzgeraldAnalyst Color Reiteration Analyst Ratings

Latest Ratings

StockFirmActionPT
KRYSHC Wainwright & Co.Maintains103.0
OTRKRBC CapitalDowngrades32.0
EVHCanaccord GenuityMaintains24.0
BMRNCanaccord GenuityMaintains91.0
ONTFCanaccord GenuityInitiates Coverage On65.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com